Physician profile
Cory Edwards
NPI 1053935114
$901.64
in general payments reported to CMS, 2019-2025
16 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $299 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $186.60 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $93.54 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $88.36 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $79.19 | 2024-2025 | |
| Pfizer INC. | $78.98 | 2024-2025 | |
| Lilly USA, LLC | $70.25 | 2024-2025 | Zepbound, Mounjaro |
| Amgen INC. | $59.42 | 2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $55.59 | 2024 | Veozah |
| Ani Pharmaceuticals, INC. | $32.86 | 2025 | Purified Cortrophin Gel |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.20 | 2025 | Caplyta |
| Organon LLC | $32.09 | 2025 | Nexplanon |
| Phathom Pharmaceuticals, INC. | $21.24 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $19.97 | 2025 | |
| Merck Sharp & Dohme LLC | $19.22 | 2025 | Verquvo |
| Inspire Medical Systems, INC. | $17.45 | 2025 | Inspire |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.68 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.